secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001062822-26-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q1 net loss narrows to $1M on $21.1M revenue; pipeline on track
-----------------------------------------------------------------------

- Total revenues $21.1M (vs $1.3M), including $20M Novo Nordisk milestone; net loss $1.0M (vs $25.3M).
- Cash and investments $199.7M at March 31, 2026; $96.5M stock sale; $100M Hercules loan facility (initial $55M funded).
- SONATA-HCM enrollment completion mid-2026; topline results expected Q1 2027.
- ZYNQUISTA NDA resubmission for T1D mid-2026; potential approval in 2026.
- LX9851 Phase 1 started by Novo Nordisk; $10M milestone earned; up to $1B in total milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000098/0001062822-26-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000098/lxrx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001062822-26-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer